GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Revenue

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Revenue : HK$8,623 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co Revenue?

Shandong Xinhua Pharmaceutical Co's revenue for the three months ended in Mar. 2024 was HK$2,688 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was HK$8,623 Mil. Shandong Xinhua Pharmaceutical Co's Revenue per Share for the three months ended in Mar. 2024 was HK$3.98. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was HK$12.58.

Warning Sign:

Shandong Xinhua Pharmaceutical Co Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Shandong Xinhua Pharmaceutical Co was -4.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 6.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 7.10% per year. During the past 10 years, the average Revenue per Share Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Shandong Xinhua Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 15.00% per year. The lowest was 3.60% per year. And the median was 7.85% per year.


Shandong Xinhua Pharmaceutical Co Revenue Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co Revenue Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,238.10 7,119.22 8,032.60 8,378.70 8,860.53

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,006.57 2,223.22 1,957.97 1,753.67 2,688.27

Competitive Comparison of Shandong Xinhua Pharmaceutical Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Xinhua Pharmaceutical Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's Revenue distribution charts can be found below:

* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's Revenue falls into.



Shandong Xinhua Pharmaceutical Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$8,623 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Xinhua Pharmaceutical Co  (HKSE:00719) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Shandong Xinhua Pharmaceutical Co Revenue Related Terms

Thank you for viewing the detailed overview of Shandong Xinhua Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Traded in Other Exchanges
Address
No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines